What does BPC-157 cost in each channel?
Prices in US dollars at the verification date. Ranges are published list or program prices where a primary source exists; notes say when a figure is a typical market range instead.
| Channel | Price (USD) | Notes |
|---|---|---|
| With insurance | Not published | Not covered. Medicare Part D and commercial pharmacy benefits cover FDA approved drugs for accepted indications; compounded or unapproved peptides are paid in cash. [4] |
| Compounded pharmacy | Not published | No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient BPC-157 under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for subcutaneous, intramuscular, oral, or topical use, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7] |
What is the list price of BPC-157?
There is no list price: BPC-157 is not an FDA approved drug. HHS's October 2026 draft policy covers conditional compounding of the single-ingredient product, but no dated price from a qualifying pharmacy has been verified yet. Products sold as research chemicals for human use are unapproved drugs and are not a comparable price.
Does insurance cover BPC-157?
Not covered by commercial plans or Medicare because it is an unapproved compounded product. Health savings account eligibility depends on a prescription and the plan administrator.
What changes the price?
- HHS's October 2026 draft policy covers only single-ingredient compounding under conditions (patient-specific prescription, allowed route, tested substance from an FDA-registered manufacturer); blends are excluded and no qualifying pharmacy price has been verified yet
Frequently asked questions
How much does BPC-157 cost without insurance?
No verified price yet. HHS's October 2026 draft enforcement discretion policy covers single-ingredient BPC-157 under conditions: HHS says it will not take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds it for subcutaneous, intramuscular, oral, or topical use, on a patient-specific prescription, from a tested substance made by an FDA-registered manufacturer, with serious adverse events reported to FDA. No dated price from a qualifying pharmacy has been verified, so none is shown. The draft is not an FDA approval or a 503A bulks listing, is not binding, and HHS may revisit it. Its 503A nomination was withdrawn in April 2026; FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). Blends are not covered, advertised clinic prices are not a comparable price, and products sold as research chemicals for human use are unapproved drugs. [1] [2] [3] [5] [6] [7]
Does insurance cover BPC-157?
Not covered by commercial plans or Medicare because it is an unapproved compounded product. Health savings account eligibility depends on a prescription and the plan administrator. [4]
What is the list price of BPC-157?
There is no list price: BPC-157 is not an FDA approved drug. HHS's October 2026 draft policy covers conditional compounding of the single-ingredient product, but no dated price from a qualifying pharmacy has been verified yet. Products sold as research chemicals for human use are unapproved drugs and are not a comparable price.
Related pages
- BPC-157: evidence, legality, and access
- BPC-157 vs ARA-290 (cibinetide)
- BPC-157 vs GHK-Cu (GHK-Cu cost)
- BPC-157 vs KPV (KPV cost)
- BPC-157 vs TB-500 (TB-500 cost)
- Tendon injury and tendinopathy: peptide evidence
- Muscle recovery and injury: peptide evidence
- Wound healing: peptide evidence
- Inflammation and inflammatory bowel disease: peptide evidence
- Inflammatory bowel disease (Crohn disease and ulcerative colitis): peptide evidence
- Irritable bowel syndrome: peptide evidence
- Traumatic brain injury: peptide evidence
- Osteoarthritis: peptide evidence
- Chronic pain: peptide evidence
- Where it is legal to get: peptide law by state
- Full cost index
From the blog
- BPC-157 before and after: reviews, results, and what controlled studies show
BPC-157 reviews and before and after stories are everywhere. Controlled results exist only in rats. What the animal healing timelines show, what the human pilots found, and why anecdotes mislead.
- BPC-157 capsules and pills: what oral BPC-157 was tested for, and what is missing
BPC-157 capsules and pills rest on rat gut, ligament, and fistula studies. No study has measured how much a capsule absorbs in people, and the two registered oral studies have posted no results.
- BPC-157 for gut health: the animal evidence and the missing human trials
BPC-157 healed ulcers, colitis, fistulas, and short bowel in rats. No human gut trial has published results. What the GI studies found, what is missing, and what has human evidence.
- BPC-157 human studies: every published report and registered clinical trial
Every published BPC-157 human report, with sample size and limits, plus every registered clinical trial on ClinicalTrials.gov. About 30 people, no control groups, and no randomized results yet.
- BPC-157 nasal spray: what is and is not known about intranasal use
No published study has given BPC-157 as a nasal spray to animals or people. What the one nose-related rat study tested, what a nasal peptide must prove, and its legal status.
- Peptides for tendon recovery, ranked by human evidence
BPC-157, TB-500, GHK-Cu, PEG-MGF, and IGF-1 LR3 ranked by our evidence grades. None has a published human tendon trial. Here is the ranking, the reasoning, and what does have human data.
Sources
- [1]FDA: July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee (BPC-157, KPV, TB-500, MOTS-c, DSIP, semax, epitalon)FDA
- [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
- [3]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list and withdrawn nominations, content current as of April 22, 2026)FDA
- [4]Medicare.gov: prescription drug coverage (Part D and outpatient drugs)
- [5]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026
- [6]Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, HHS notice of availability of a draft policy, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496 (public inspection copy; publication scheduled October 30, 2026)Federal Register, 2026
- [7]HHS: draft enforcement discretion policy for 503A compounding using certain peptide bulk drug substances, with Appendix A (covered peptides) and Appendix B (identity, routes, and committee history), October 28, 20262026